Colonic Diseases  >>  Erivedge (vismodegib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erivedge (vismodegib) / Roche
NCT00636610: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

Completed
2
199
NA
Vismodegib 150 mg, GDC-0449, Erivedge, Placebo to vismodegib, Bevacizumab, Modified FOLFOX, FOLFIRI
Genentech, Inc.
Metastatic Colorectal Cancer
12/10
12/10
NCT00959647: A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Completed
2
19
US
Vismodegib, Erivedge, GDC-0449, RO5450815, FOLFOX, FOLFIRI, Bevacizumab, Avastin
Genentech, Inc.
Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
01/14
01/14

Download Options